We are heading to Liverpool on 8 February to join in the discussion at the 2024 BioInfect Conference, where Michael Graz will be showcasing the potential of Disperazol as a co-treatment for UTI Infections caused by Gram negative pathogens, including E.coli and P.aeruginosa. Look out for Disperazol Pharma’s poster entitled “Boosting the efficacy of SoC antibiotics against recurrent Pseudomonas aeruginosa biofilm infections”.